메뉴 건너뛰기




Volumn 8, Issue 5, 2011, Pages 292-301

HCC and angiogenesis: Possible targets and future directions

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; BIOLOGICAL MARKER; BRIVANIB ALANINATE; CEDIRANIB; CYTOTOXIC AGENT; DOXORUBICIN; ERLOTINIB; FORETINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; LINIFANIB; ORANTINIB; OXALIPLATIN; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; SORAFENIB; STROMAL CELL DERIVED FACTOR 1ALPHA; SUNITINIB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VATALANIB;

EID: 79955580873     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.30     Document Type: Review
Times cited : (469)

References (147)
  • 1
    • 78049485263 scopus 로고    scopus 로고
    • Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
    • Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917 (2010).
    • (2010) Int. J. Cancer , vol.127 , pp. 2893-2917
    • Ferlay, J.1
  • 2
    • 19644381818 scopus 로고    scopus 로고
    • Hepatocellular carcinoma: The need for progress
    • DOI 10.1200/JCO.2005.03.196
    • Thomas, M. B. & Zhu, A. X. Hepatocellular carcinoma: the need for progress. J. Clin. Oncol. 23, 2892-2899, (2005). (Pubitemid 46224106)
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.13 , pp. 2892-2899
    • Thomas, M.B.1    Zhu, A.X.2
  • 3
    • 0003120252 scopus 로고    scopus 로고
    • eds DeVita, V. T., Hellman, S. & Rosenberg, S. A.), (Lippincott Williams and Wilkins, Philadelphia, PA, USA
    • Fong, Y., Kemeny, N. & Lawrence, T. S. in Cancer, Principles and Practice of Oncology 6th edn (eds DeVita, V. T., Hellman, S. & Rosenberg, S. A.) 1162-1203 (Lippincott Williams and Wilkins, Philadelphia, PA, USA, 2001).
    • (2001) Cancer, Principles and Practice of Oncology 6th Edn , pp. 1162-1203
    • Fong, Y.1    Kemeny, N.2    Lawrence, T.S.3
  • 4
    • 33947732977 scopus 로고    scopus 로고
    • Angiogenesis: An organizing principle for drug discovery?
    • DOI 10.1038/nrd2115, PII NRD2115
    • Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6, 273-286 (2007). (Pubitemid 46505878)
    • (2007) Nature Reviews Drug Discovery , vol.6 , Issue.4 , pp. 273-286
    • Folkman, J.1
  • 5
    • 77950960449 scopus 로고    scopus 로고
    • Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease
    • Van de Veire, S. et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 141, 178-190 (2010).
    • (2010) Cell , vol.141 , pp. 178-190
    • Van De Veire, S.1
  • 6
    • 47949116252 scopus 로고    scopus 로고
    • Sorafenib in advanced hepatocellular carcinoma
    • Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
    • (2008) N. Engl. J. Med. , vol.359 , pp. 378-390
    • Llovet, J.M.1
  • 8
    • 3042761526 scopus 로고    scopus 로고
    • Angiogenesis in hepatocellular carcinoma: The retrospectives and perspectives
    • Sun, H. C. & Tang, Z. Y. Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J. Cancer Res. Clin. Oncol. 130, 307-319 (2004).
    • (2004) J. Cancer Res. Clin. Oncol. , vol.130 , pp. 307-319
    • Sun, H.C.1    Tang, Z.Y.2
  • 9
    • 11844254414 scopus 로고    scopus 로고
    • Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
    • DOI 10.1126/science.1104819
    • Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005). (Pubitemid 40093472)
    • (2005) Science , vol.307 , Issue.5706 , pp. 58-62
    • Jain, R.K.1
  • 10
    • 38749084161 scopus 로고    scopus 로고
    • Taming vessels to treat cancer
    • Jain, R. K. Taming vessels to treat cancer. Sci. Am. 298, 56-63 (2008). (Pubitemid 351182556)
    • (2008) Scientific American , vol.298 , Issue.1 , pp. 56-63
    • Jain, R.K.1
  • 11
    • 40649109728 scopus 로고    scopus 로고
    • The wolf in sheep's clothing: The role of interleukin-6 in immunity, inflammation and cancer
    • Naugler, W. E. & Karin, M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med. 14, 109-119 (2008).
    • (2008) Trends Mol. Med. , vol.14 , pp. 109-119
    • Naugler, W.E.1    Karin, M.2
  • 12
    • 67649946279 scopus 로고    scopus 로고
    • Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study
    • Zhu, A. X. et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol. 27, 3027-3035 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , pp. 3027-3035
    • Zhu, A.X.1
  • 14
    • 45849135992 scopus 로고    scopus 로고
    • Vascular changes in hepatocellular carcinoma
    • Yang, Z. F. & Poon, R. T. Vascular changes in hepatocellular carcinoma. Anat. Rec. (Hoboken) 291, 721-734 (2008).
    • (2008) Anat. Rec. (Hoboken) , vol.291 , pp. 721-734
    • Yang, Z.F.1    Poon, R.T.2
  • 15
    • 0030884164 scopus 로고    scopus 로고
    • Effect of host microenvironment on the microcirculation of human colon adenocarcinoma
    • Fukumura, D., Yuan, F., Monsky, W. L., Chen, Y. & Jain, R. K. Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am. J. Pathol. 151, 679-688 (1997). (Pubitemid 27385599)
    • (1997) American Journal of Pathology , vol.151 , Issue.3 , pp. 679-688
    • Fukumura, D.1    Yuan, F.2    Monsky, W.L.3    Chen, Y.4    Jain, R.K.5
  • 16
    • 34547690632 scopus 로고    scopus 로고
    • Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma
    • DOI 10.1111/j.1440-1746.2007.04997.x
    • Wu, X. Z., Xie, G. R. & Chen, D. Hypoxia and hepatocellular carcinoma: the therapeutic target for hepatocellular carcinoma. J. Gastroenterol. Hepatol. 22, 1178-1182 (2007). (Pubitemid 47222667)
    • (2007) Journal of Gastroenterology and Hepatology , vol.22 , Issue.8 , pp. 1178-1182
    • Wu, X.-Z.1    Xie, G.-R.2    Chen, D.3
  • 17
    • 34047260282 scopus 로고    scopus 로고
    • Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: Insights from a mathematical model
    • DOI 10.1158/0008-5472.CAN-06-4102
    • Jain, R. K., Tong, R. T. & Munn, L. L. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 67, 2729-2735 (2007). (Pubitemid 46548961)
    • (2007) Cancer Research , vol.67 , Issue.6 , pp. 2729-2735
    • Jain, R.K.1    Tong, R.T.2    Munn, L.L.3
  • 18
    • 0037423321 scopus 로고    scopus 로고
    • Angiogenesis-independent endothelial protection of liver: Role of VEGFR-1
    • LeCouter, J. et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299, 890-893 (2003).
    • (2003) Science , vol.299 , pp. 890-893
    • Lecouter, J.1
  • 19
    • 74549133965 scopus 로고    scopus 로고
    • Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development
    • Lichtenberger, B. M. et al. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell 140, 268-279 (2010).
    • (2010) Cell , vol.140 , pp. 268-279
    • Lichtenberger, B.M.1
  • 20
    • 0035881307 scopus 로고    scopus 로고
    • Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo
    • Fukumura, D. et al. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 61, 6020-6024 (2001). (Pubitemid 32762531)
    • (2001) Cancer Research , vol.61 , Issue.16 , pp. 6020-6024
    • Fukumura, D.1    Xu, L.2    Chen, Y.3    Gohongi, T.4    Seed, B.5    Jain, R.K.6
  • 21
    • 0034648765 scopus 로고    scopus 로고
    • Angiogenesis in cancer and other diseases
    • Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2000).
    • (2000) Nature , vol.407 , pp. 249-257
    • Carmeliet, P.1    Jain, R.K.2
  • 22
    • 0036842215 scopus 로고    scopus 로고
    • Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
    • DOI 10.1200/JCO.2002.10.088
    • Dvorak, H. F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20, 4368-4380 (2002). (Pubitemid 35266299)
    • (2002) Journal of Clinical Oncology , vol.20 , Issue.21 , pp. 4368-4380
    • Dvorak, H.F.1
  • 23
    • 33745559710 scopus 로고    scopus 로고
    • The role of nitric oxide in tumour progression
    • DOI 10.1038/nrc1910, PII N1910
    • Fukumura, D., Kashiwagi, S. & Jain, R. K. The role of nitric oxide in tumour progression. Nat. Rev. Cancer 6, 521-534 (2006). (Pubitemid 43980541)
    • (2006) Nature Reviews Cancer , vol.6 , Issue.7 , pp. 521-534
    • Fukumura, D.1    Kashiwagi, S.2    Jain, R.K.3
  • 25
    • 0000391746 scopus 로고    scopus 로고
    • Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
    • Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2, 737-744 (2000).
    • (2000) Nat. Cell Biol. , vol.2 , pp. 737-744
    • Bergers, G.1
  • 27
  • 28
    • 0038376002 scopus 로고    scopus 로고
    • Molecular regulation of vessel maturation
    • DOI 10.1038/nm0603-685
    • Jain, R. K. Molecular regulation of vessel maturation. Nat. Med. 9, 685-693 (2003). (Pubitemid 36749217)
    • (2003) Nature Medicine , vol.9 , Issue.6 , pp. 685-693
    • Jain, R.K.1
  • 29
    • 0037699954 scopus 로고    scopus 로고
    • The biology of VEGF and its receptors
    • DOI 10.1038/nm0603-669
    • Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 9, 669-676 (2003). (Pubitemid 36749215)
    • (2003) Nature Medicine , vol.9 , Issue.6 , pp. 669-676
    • Ferrara, N.1    Gerber, H.-P.2    LeCouter, J.3
  • 30
    • 7244250405 scopus 로고    scopus 로고
    • Angiogenesis and hepatocellular carcinoma
    • DOI 10.1016/j.jhep.2004.09.006, PII S0168827804003940
    • Semela, D. & Dufour, J. F. Angiogenesis and hepatocellular carcinoma. J. Hepatol. 41, 864-880 (2004). (Pubitemid 39434320)
    • (2004) Journal of Hepatology , vol.41 , Issue.5 , pp. 864-880
    • Semela, D.1    Dufour, J.-F.2
  • 31
    • 33748653168 scopus 로고    scopus 로고
    • Emerging drugs for hepatocellular carcinoma
    • DOI 10.1517/14728214.11.3.469
    • Roberts, L. R. & Gores, G. J. Emerging drugs for hepatocellular carcinoma. Expert Opin. Emerg. Drugs 11, 469-487 (2006). (Pubitemid 44386371)
    • (2006) Expert Opinion on Emerging Drugs , vol.11 , Issue.3 , pp. 469-487
    • Roberts, L.R.1    Gores, G.J.2
  • 32
    • 38449116573 scopus 로고    scopus 로고
    • Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation
    • DOI 10.1097/01.tp.0000287596.91520.1a, PII 0000789020071127000008
    • Mas, V. R., Maluf, D. G., Archer, K. J., Yanek, K. C. & Fisher, R. A. Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation. Transplantation 84, 1262-1271 (2007). (Pubitemid 351339314)
    • (2007) Transplantation , vol.84 , Issue.10 , pp. 1262-1271
    • Mas, V.R.1    Maluf, D.G.2    Archer, K.J.3    Yanek, K.C.4    Fisher, R.A.5
  • 33
    • 0034802560 scopus 로고    scopus 로고
    • Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma
    • DOI 10.1016/S0002-9610(01)00708-5, PII S0002961001007085
    • Poon, R. T. et al. Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am. J. Surg. 182, 298-304 (2001). (Pubitemid 32918381)
    • (2001) American Journal of Surgery , vol.182 , Issue.3 , pp. 298-304
    • Poon, R.T.-P.1    Ng, I.O.-L.2    Lau, C.3    Yu, W.-C.4    Fan, S.-T.5    Wong, J.6
  • 34
    • 0035132143 scopus 로고    scopus 로고
    • Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: A prospective study
    • DOI 10.1097/00000658-200102000-00012
    • Poon, R. T. et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann. Surg. 233, 227-235 (2001). (Pubitemid 32106077)
    • (2001) Annals of Surgery , vol.233 , Issue.2 , pp. 227-235
    • Poon, R.T.-P.1    Ng, I.O.-L.2    Lau, C.3    Zhu, L.-X.4    Yu, W.-C.5    Lo, C.-M.6    Fan, S.-T.7    Wong, J.8
  • 35
    • 0036254553 scopus 로고    scopus 로고
    • Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: A comparison with angiopoietin/Tie pathway
    • Dhar, D. K. et al. Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway. Anticancer Res. 22, 379-386 (2002). (Pubitemid 34475326)
    • (2002) Anticancer Research , vol.22 , Issue.1 A , pp. 379-386
    • Dhar, D.K.1    Naora, H.2    Yamanoi, A.3    Ono, T.4    Kohno, H.5    Otani, H.6    Nagasue, N.7
  • 36
    • 0031778206 scopus 로고    scopus 로고
    • Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver
    • DOI 10.1002/hep.510270613
    • El-Assal, O. N. et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 27, 1554-1562 (1998). (Pubitemid 28264678)
    • (1998) Hepatology , vol.27 , Issue.6 , pp. 1554-1562
    • El-Assal, O.N.1    Yamanoi, A.2    Soda, Y.3    Yamaguchi, M.4    Igarashi, M.5    Yamamoto, A.6    Nabika, T.7    Nagasue, N.8
  • 37
    • 0004623809 scopus 로고    scopus 로고
    • Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis
    • Park, Y. N., Kim, Y. B., Yang, K. M. & Park, C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch. Pathol. Lab. Med. 124, 1061-1065 (2000). (Pubitemid 30602050)
    • (2000) Archives of Pathology and Laboratory Medicine , vol.124 , Issue.7 , pp. 1061-1065
    • Park, Y.N.1    Kim, Y.-B.2    Yang, K.M.3    Park, C.4
  • 38
    • 0031807538 scopus 로고    scopus 로고
    • Expression of vascular endothelial growth factor in human hepatocellular carcinoma
    • DOI 10.1002/hep.510280111
    • Yamaguchi, R. et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28, 68-77 (1998). (Pubitemid 28299987)
    • (1998) Hepatology , vol.28 , Issue.1 , pp. 68-77
    • Yamaguchi, R.1    Yano, H.2    Iemura, A.3    Ogasawara, S.4    Haramaki, M.5    Kojiro, M.6
  • 39
    • 0031955570 scopus 로고    scopus 로고
    • Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma
    • Li, X. M., Tang, Z. Y., Zhou, G., Lui, Y. K. & Ye, S. L. Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 17, 13-17 (1998). (Pubitemid 28215959)
    • (1998) Journal of Experimental and Clinical Cancer Research , vol.17 , Issue.1 , pp. 13-17
    • Li, X.M.1    Tang, Z.Y.2    Zhou, G.3    Lui, Y.K.4    Ye, S.L.5
  • 40
    • 20344371480 scopus 로고    scopus 로고
    • Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma
    • Yao, D. F. et al. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 4, 220-226 (2005).
    • (2005) Hepatobiliary Pancreat. Dis. Int. , vol.4 , pp. 220-226
    • Yao, D.F.1
  • 42
    • 4944234987 scopus 로고    scopus 로고
    • Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma
    • DOI 10.1002/bjs.4594
    • Poon, R. T. et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br. J. Surg. 91, 1354-1360 (2004). (Pubitemid 39331462)
    • (2004) British Journal of Surgery , vol.91 , Issue.10 , pp. 1354-1360
    • Poon, R.T.P.1    Ho, J.W.Y.2    Tong, C.S.W.3    Lau, C.4    Ng, I.O.L.5    Fan, S.-T.6
  • 43
  • 44
    • 70350506052 scopus 로고    scopus 로고
    • High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma
    • Tamesa, T. et al. High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma. Hepatogastroenterology 56, 1122-1126 (2009).
    • (2009) Hepatogastroenterology , vol.56 , pp. 1122-1126
    • Tamesa, T.1
  • 46
    • 4644289324 scopus 로고    scopus 로고
    • Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level
    • Li, X., Feng, G. S., Zheng, C. S., Zhuo, C. K. & Liu, X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J. Gastroenterol. 10, 2878-2882 (2004). (Pubitemid 39303010)
    • (2004) World Journal of Gastroenterology , vol.10 , Issue.19 , pp. 2878-2882
    • Li, X.1    Feng, G.-S.2    Zheng, C.-S.3    Zhuo, C.-K.4    Liu, X.5
  • 47
    • 54949109005 scopus 로고    scopus 로고
    • Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients
    • Shim, J. H. et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci. 99, 2037-2044 (2008).
    • (2008) Cancer Sci. , vol.99 , pp. 2037-2044
    • Shim, J.H.1
  • 49
    • 34249900712 scopus 로고    scopus 로고
    • High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: Importance of tumor biomarker in ablative therapies
    • DOI 10.1245/s10434-007-9366-z
    • Poon, R. T. et al. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann. Surg. Oncol. 14, 1835-1845 (2007). (Pubitemid 46870942)
    • (2007) Annals of Surgical Oncology , vol.14 , Issue.6 , pp. 1835-1845
    • Poon, R.T.P.1    Lau, C.2    Pang, R.3    Ng, K.K.4    Yuen, J.5    Fan, S.T.6
  • 50
    • 4444366693 scopus 로고    scopus 로고
    • Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection
    • Cui, J., Dong, B. W., Liang, P., Yu, X. L. & Yu, D. J. Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection. World J. Gastroenterol. 10, 1533-1536 (2004). (Pubitemid 39206824)
    • (2004) World Journal of Gastroenterology , vol.10 , Issue.10 , pp. 1533-1536
    • Cui, J.1    Dong, B.-W.2    Liang, P.3    Yu, X.-L.4    Yu, D.-J.5
  • 51
    • 69049116144 scopus 로고    scopus 로고
    • High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection
    • Hu, J. et al. High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection. J. Cancer Res. Clin. Oncol. 135, 1359-1367 (2009).
    • (2009) J. Cancer Res. Clin. Oncol. , vol.135 , pp. 1359-1367
    • Hu, J.1
  • 52
    • 58149329048 scopus 로고    scopus 로고
    • Expression of vascular endothelial growth factor (VEGF) family members and prognosis after hepatic resection in HBV-related hepatocellular carcinoma [Korean]
    • Moon, J. I. et al. Expression of vascular endothelial growth factor (VEGF) family members and prognosis after hepatic resection in HBV-related hepatocellular carcinoma [Korean]. Korean J. Hepatol. 14, 185-196 (2008).
    • (2008) Korean J. Hepatol. , vol.14 , pp. 185-196
    • Moon, J.I.1
  • 53
    • 1542685212 scopus 로고    scopus 로고
    • Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: A prospective study
    • Jeng, K. S. et al. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. World J. Gastroenterol. 10, 643-648 (2004).
    • (2004) World J. Gastroenterol. , vol.10 , pp. 643-648
    • Jeng, K.S.1
  • 54
    • 1542790444 scopus 로고    scopus 로고
    • Is the vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma of prognostic value after resection?
    • Jeng, K. S. et al. Is the vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma of prognostic value after resection? World J. Gastroenterol. 10, 676-681 (2004).
    • (2004) World J. Gastroenterol. , vol.10 , pp. 676-681
    • Jeng, K.S.1
  • 55
    • 34047159945 scopus 로고    scopus 로고
    • Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma
    • Ho, M. C. et al. Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma. Cancer Lett. 250, 237-249 (2007).
    • (2007) Cancer Lett. , vol.250 , pp. 237-249
    • Ho, M.C.1
  • 56
    • 33645740560 scopus 로고    scopus 로고
    • Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: Importance of angiopoietin-2 and hypoxia-induced factor-1 alpha
    • Wada, H. et al. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int. 26, 414-423 (2006).
    • (2006) Liver Int. , vol.26 , pp. 414-423
    • Wada, H.1
  • 57
    • 57749189578 scopus 로고    scopus 로고
    • Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial
    • Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34 (2009).
    • (2009) Lancet Oncol. , vol.10 , pp. 25-34
    • Cheng, A.L.1
  • 58
    • 38049097938 scopus 로고    scopus 로고
    • Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling
    • McDermott, U. et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Natl Acad. Sci. USA 104, 19936-19941 (2007).
    • (2007) Proc. Natl Acad. Sci. USA , vol.104 , pp. 19936-19941
    • McDermott, U.1
  • 59
    • 78649972858 scopus 로고    scopus 로고
    • Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: Results of a phase I study
    • Dufour, J. F. et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist 15, 1198-1204 (2010).
    • (2010) Oncologist , vol.15 , pp. 1198-1204
    • Dufour, J.F.1
  • 60
    • 79551521053 scopus 로고    scopus 로고
    • Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08
    • Allegra, C. J. et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J. Clin. Oncol. 29, 11-16 (2010).
    • (2010) J. Clin. Oncol. , vol.29 , pp. 11-16
    • Allegra, C.J.1
  • 64
    • 0036769119 scopus 로고    scopus 로고
    • Regulation and targets of receptor tyrosine kinases
    • Pawson, T. Regulation and targets of receptor tyrosine kinases. Eur. J. Cancer 38 (Suppl. 5), S3-S10 (2002).
    • (2002) Eur. J. Cancer , vol.38 , Issue.SUPPL. 5
    • Pawson, T.1
  • 65
    • 67651165187 scopus 로고    scopus 로고
    • Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: An open-label, multicentre, phase II study
    • Faivre, S. et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 10, 794-800 (2009).
    • (2009) Lancet Oncol. , vol.10 , pp. 794-800
    • Faivre, S.1
  • 66
    • 58049201181 scopus 로고    scopus 로고
    • Phase II study of sunitinib malate in adult patients with metastatic or surgically unresectable hepatocellular carcinoma (HCC) [abstract]
    • Hoda, D. et al. Phase II study of sunitinib malate in adult patients with metastatic or surgically unresectable hepatocellular carcinoma (HCC) [abstract]. Proc. 2008 Gastrointestinal Cancers Symp. a267 (2008).
    • (2008) Proc. 2008 Gastrointestinal Cancers Symp. , vol.A267
    • Hoda, D.1
  • 67
    • 77950546450 scopus 로고    scopus 로고
    • Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06)
    • Koeberle, D. et al. Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist 15, 285-292 (2010).
    • (2010) Oncologist , vol.15 , pp. 285-292
    • Koeberle, D.1
  • 69
    • 68949145218 scopus 로고    scopus 로고
    • Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
    • Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584-3590 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , pp. 3584-3590
    • Motzer, R.J.1
  • 70
    • 60649087564 scopus 로고    scopus 로고
    • Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
    • Ebos, J. M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239 (2009).
    • (2009) Cancer Cell , vol.15 , pp. 232-239
    • Ebos, J.M.1
  • 71
    • 84860254547 scopus 로고    scopus 로고
    • A phase II study of ramucirumab as first-line monotherapy in patients with advanced hepatocellular carcinoma [abstract]
    • Zhu, A. X. et al. A phase II study of ramucirumab as first-line monotherapy in patients with advanced hepatocellular carcinoma [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a4083 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , Issue.15 SUPPL.
    • Zhu, A.X.1
  • 72
    • 0034796595 scopus 로고    scopus 로고
    • Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
    • DOI 10.1038/nm0901-987
    • Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat. Med. 7, 987-989 (2001). (Pubitemid 32937367)
    • (2001) Nature Medicine , vol.7 , Issue.9 , pp. 987-989
    • Jain, R.K.1
  • 74
    • 46449091500 scopus 로고    scopus 로고
    • Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma
    • Siegel, A. B. et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol. 26, 2992-2998 (2008).
    • (2008) J. Clin. Oncol. , vol.26 , pp. 2992-2998
    • Siegel, A.B.1
  • 76
    • 84984578313 scopus 로고    scopus 로고
    • Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
    • Hsu, C. H. et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br. J. Cancer 102, 981-986 (2010).
    • (2010) Br. J. Cancer , vol.102 , pp. 981-986
    • Hsu, C.H.1
  • 77
    • 36549089272 scopus 로고    scopus 로고
    • Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma: A phase II study [abstract]
    • Sun, W. et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma: a phase II study [abstract]. J. Clin. Oncol. 25 (18 Suppl.), a4574 (2007).
    • (2007) J. Clin. Oncol. , vol.25 , Issue.18 SUPPL.
    • Sun, W.1
  • 78
    • 38049092474 scopus 로고    scopus 로고
    • Bevacizumab in patients with advanced hepatocellular carcinoma: Preliminary results of a phase II study with circulating endothelial cell monitoring [abstract]
    • Malka, D. et al. Bevacizumab in patients with advanced hepatocellular carcinoma: preliminary results of a phase II study with circulating endothelial cell monitoring [abstract]. J. Clin. Oncol. 25 (18 Suppl.), a4570 (2007).
    • (2007) J. Clin. Oncol. , vol.25 , Issue.18 SUPPL.
    • Malka, D.1
  • 79
    • 60849124241 scopus 로고    scopus 로고
    • Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma
    • Thomas, M. B. et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J. Clin. Oncol. 27, 843-850 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , pp. 843-850
    • Thomas, M.B.1
  • 81
    • 78650847886 scopus 로고    scopus 로고
    • Linifanib phase II trial in patients with advanced hepatocellular carcinoma [abstract]
    • Toh, H. et al. Linifanib phase II trial in patients with advanced hepatocellular carcinoma [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a4038 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , Issue.15 SUPPL.
    • Toh, H.1
  • 83
    • 38049030409 scopus 로고    scopus 로고
    • NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma-interim review of toxicity [abstract]
    • Alberts, S. R. et al. NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma-interim review of toxicity [abstract]. Proc. 2007 Gastrointestinal Cancers Symp. a186 (2007).
    • (2007) Proc. 2007 Gastrointestinal Cancers Symp.
    • Alberts, S.R.1
  • 84
    • 71449116258 scopus 로고    scopus 로고
    • A phase I study of pazopanib in patients with advanced hepatocellular carcinoma [abstract]
    • Yau, C. C. et al. A phase I study of pazopanib in patients with advanced hepatocellular carcinoma [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a3561 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , Issue.15 SUPPL.
    • Yau, C.C.1
  • 86
    • 0037099598 scopus 로고    scopus 로고
    • PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging
    • Drevs, J. et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 62, 4015-4022 (2002). (Pubitemid 34791068)
    • (2002) Cancer Research , vol.62 , Issue.14 , pp. 4015-4022
    • Drevs, J.1    Muller-Driver, R.2    Wittig, C.3    Fuxius, S.4    Esser, N.5    Hugenschmidt, H.6    Konerding, M.A.7    Allegrini, P.R.8    Wood, J.9    Hennig, J.10    Unger, C.11    Marme, D.12
  • 87
    • 39849106728 scopus 로고    scopus 로고
    • Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics of PTK787/ZK 222584 in patients with unresectable hepatocellular carcinoma [abstract]
    • Koch, I. et al. Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics of PTK787/ZK 222584 in patients with unresectable hepatocellular carcinoma [abstract]. J. Clin. Oncol. 23 (16 Suppl.), a4134 (2005).
    • (2005) J. Clin. Oncol. , vol.23 , Issue.16 SUPPL.
    • Koch, I.1
  • 88
    • 78249288161 scopus 로고    scopus 로고
    • Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: Implication for antiangiogenic approach to hepatocellular carcinoma
    • Yau, T. et al. Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma. Cancer 116, 5022-5029 (2010).
    • (2010) Cancer , vol.116 , pp. 5022-5029
    • Yau, T.1
  • 89
    • 58149175849 scopus 로고    scopus 로고
    • Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma
    • Huynh, H. et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin. Cancer Res. 14, 6146-6153 (2008).
    • (2008) Clin. Cancer Res. , vol.14 , pp. 6146-6153
    • Huynh, H.1
  • 90
    • 72949117051 scopus 로고    scopus 로고
    • TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model
    • Ohta, M. et al. TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model. Surg. Today 39, 1046-1053 (2009).
    • (2009) Surg. Today , vol.39 , pp. 1046-1053
    • Ohta, M.1
  • 91
    • 74549223962 scopus 로고    scopus 로고
    • An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma [abstract]
    • Raoul, J. L. et al. An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a4577 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , Issue.15 SUPPL.
    • Raoul, J.L.1
  • 92
    • 79953803472 scopus 로고    scopus 로고
    • A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma
    • Kanai, F. et al. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother. Pharmacol. 67, 315-324 (2011).
    • (2011) Cancer Chemother. Pharmacol. , vol.67 , pp. 315-324
    • Kanai, F.1
  • 93
    • 77954236265 scopus 로고    scopus 로고
    • A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2
    • Eder, J. P. et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin. Cancer Res. 16, 3507-3516 (2010).
    • (2010) Clin. Cancer Res. , vol.16 , pp. 3507-3516
    • Eder, J.P.1
  • 94
    • 44449085884 scopus 로고    scopus 로고
    • Design and endpoints of clinical trials in hepatocellular carcinoma
    • Llovet, J. M. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100, 698-711 (2008).
    • (2008) J. Natl Cancer Inst. , vol.100 , pp. 698-711
    • Llovet, J.M.1
  • 95
    • 69549131042 scopus 로고    scopus 로고
    • Development of sunitinib in hepatocellular carcinoma: Rationale, early clinical experience and correlative studies
    • Zhu, A. X., Duda, D. G., Sahani, D. V. & Jain, R. K. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience and correlative studies. Cancer J. 15, 263-268 (2009).
    • (2009) Cancer J. , vol.15 , pp. 263-268
    • Zhu, A.X.1    Duda, D.G.2    Sahani, D.V.3    Jain, R.K.4
  • 96
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205-216 (2000).
    • (2000) J. Natl. Cancer Inst. , vol.92 , pp. 205-216
    • Therasse, P.1
  • 97
    • 73349110120 scopus 로고    scopus 로고
    • Sunitinib in hepatocellular carcinoma: Redefining appropriate dosing, schedule, and activity end points
    • Faivre, S. J., Bouattour, M., Dreyer, C. & Raymond, E. Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points. J. Clin. Oncol. 27, e248-e250 (2009).
    • (2009) J. Clin. Oncol. , vol.27
    • Faivre, S.J.1    Bouattour, M.2    Dreyer, C.3    Raymond, E.4
  • 100
    • 42949161642 scopus 로고    scopus 로고
    • Radiologic measurements of tumor response to treatment: Practical approaches and limitations
    • Suzuki, C. et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 28, 329-344 (2008).
    • (2008) Radiographics , vol.28 , pp. 329-344
    • Suzuki, C.1
  • 101
    • 60049085346 scopus 로고    scopus 로고
    • Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: Are response evaluation criteria in solid tumors reliable?
    • Forner, A. et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115, 616-623 (2009).
    • (2009) Cancer , vol.115 , pp. 616-623
    • Forner, A.1
  • 102
    • 67650380136 scopus 로고    scopus 로고
    • Biomarkers of response and resistance to antiangiogenic therapy
    • Jain, R. K. et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 6, 327-338 (2009).
    • (2009) Nat. Rev. Clin. Oncol. , vol.6 , pp. 327-338
    • Jain, R.K.1
  • 103
    • 33747830764 scopus 로고    scopus 로고
    • Hepatocellular carcinoma pathogenesis: From genes to environment
    • DOI 10.1038/nrc1934, PII NRC1934
    • Farazi, P. A. & DePinho, R. A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6, 674-687 (2006). (Pubitemid 44286000)
    • (2006) Nature Reviews Cancer , vol.6 , Issue.9 , pp. 674-687
    • Farazi, P.A.1    DePinho, R.A.2
  • 104
    • 0036831559 scopus 로고    scopus 로고
    • Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy?
    • DOI 10.1038/nrc925
    • Rafii, S., Lyden, D., Benezra, R., Hattori, K. & Heissig, B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer 2, 826-835 (2002). (Pubitemid 37328901)
    • (2002) Nature Reviews Cancer , vol.2 , Issue.11 , pp. 826-835
    • Rafii, S.1    Lyden, D.2    Benezra, R.3    Hattori, K.4    Heissig, B.5
  • 105
    • 79951818748 scopus 로고    scopus 로고
    • Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: Kinetics and potential biomarker value
    • Zhu, A. X. et al. Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: Kinetics and potential biomarker value. Clin. Cancer Res. 17, 918-927 (2011).
    • (2011) Clin. Cancer Res. , vol.17 , pp. 918-927
    • Zhu, A.X.1
  • 106
    • 70449523183 scopus 로고    scopus 로고
    • Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
    • Kumar, R. et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br. J. Cancer 101, 1717-1723 (2009).
    • (2009) Br. J. Cancer , vol.101 , pp. 1717-1723
    • Kumar, R.1
  • 107
    • 69249149754 scopus 로고    scopus 로고
    • A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis [abstract]
    • Toh, H., Chen, P. & Carr, B. et al. A phase II study of ABT-869 in hepatocellular carcinoma (HCC): interim analysis [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a4581 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , Issue.15 SUPPL.
    • Toh, H.1    Chen, P.2    Carr, B.3
  • 108
    • 77957559384 scopus 로고    scopus 로고
    • Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
    • Shao, Y. Y. et al. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 116, 4590-4596 (2010).
    • (2010) Cancer , vol.116 , pp. 4590-4596
    • Shao, Y.Y.1
  • 109
    • 58049197319 scopus 로고    scopus 로고
    • Circulating biomarkers of sunitinib in patients with unresectable hepatocellular carcinoma (HCC): Analysis of correlations with outcome and tumor imaging parameters [abstact]
    • DePrimo, S. E. et al. Circulating biomarkers of sunitinib in patients with unresectable hepatocellular carcinoma (HCC): analysis of correlations with outcome and tumor imaging parameters [abstact]. J. Clin. Oncol. 26 (Suppl.), a4593 (2008).
    • (2008) J. Clin. Oncol. , vol.26 , Issue.SUPPL.
    • Deprimo, S.E.1
  • 110
    • 74549155611 scopus 로고    scopus 로고
    • Circulating endothelial cells (CECs) and angiogenic proteins monitoring in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with bevacizumab [abstract]
    • Boige, V. et al. Circulating endothelial cells (CECs) and angiogenic proteins monitoring in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with bevacizumab [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a4597 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , Issue.15 SUPPL.
    • Boige, V.1
  • 111
    • 84886354305 scopus 로고    scopus 로고
    • Molecular predictors of response to antiangiogenic therapy in HCC: Data from bevacizumab and erlotinib phase II study [abstract]
    • Kaseb, A. O. et al. Molecular predictors of response to antiangiogenic therapy in HCC: Data from bevacizumab and erlotinib phase II study [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a4046 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , Issue.15 SUPPL.
    • Kaseb, A.O.1
  • 112
    • 79955617020 scopus 로고    scopus 로고
    • Prognostic values of baseline circulating endothelial progenitor level for advanced hepatocellular carcinoma (HCC) patients under antiangiogenic therapy [abstract]
    • Shao, Y. et al. Prognostic values of baseline circulating endothelial progenitor level for advanced hepatocellular carcinoma (HCC) patients under antiangiogenic therapy [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a4063 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , Issue.15 SUPPL.
    • Shao, Y.1
  • 113
    • 2442621619 scopus 로고    scopus 로고
    • Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
    • Ferrara, N., Hillan, K. J., Gerber, H. P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400 (2004). (Pubitemid 38618122)
    • (2004) Nature Reviews Drug Discovery , vol.3 , Issue.5 , pp. 391-400
    • Ferrara, N.1    Hillan, K.J.2    Gerber, H.-P.3    Novotny, W.4
  • 116
    • 30744479430 scopus 로고    scopus 로고
    • Angiogenesis in life, disease and medicine
    • DOI 10.1038/nature04478, PII NATURE04478
    • Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932-936 (2005). (Pubitemid 43093958)
    • (2005) Nature , vol.438 , Issue.7070 , pp. 932-936
    • Carmeliet, P.1
  • 117
    • 33847169820 scopus 로고    scopus 로고
    • Vascular biology: Vessel guidance
    • DOI 10.1038/445722a, PII 445722A
    • Gridley, T. Vascular biology: vessel guidance. Nature 445, 722-723 (2007). (Pubitemid 46279702)
    • (2007) Nature , vol.445 , Issue.7129 , pp. 722-723
    • Gridley, T.1
  • 118
    • 31544448010 scopus 로고    scopus 로고
    • Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function
    • DOI 10.1182/blood-2005-03-1000
    • Williams, C. K., Li, J. L., Murga, M., Harris, A. L. & Tosato, G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107, 931-939 (2006). (Pubitemid 43156289)
    • (2006) Blood , vol.107 , Issue.3 , pp. 931-939
    • Williams, C.K.1    Li, J.-L.2    Murga, M.3    Harris, A.L.4    Tosato, G.5
  • 122
    • 66149133341 scopus 로고    scopus 로고
    • Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice
    • Vincent, F. et al. Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice. Cancer Res. 69, 2853-2860 (2009).
    • (2009) Cancer Res. , vol.69 , pp. 2853-2860
    • Vincent, F.1
  • 126
    • 74549217325 scopus 로고    scopus 로고
    • Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation
    • He, G. et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 17, 286-297 (2010).
    • (2010) Cancer Cell , vol.17 , pp. 286-297
    • He, G.1
  • 127
    • 74549167737 scopus 로고    scopus 로고
    • Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression
    • Park, E. J. et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197-208 (2010).
    • (2010) Cell , vol.140 , pp. 197-208
    • Park, E.J.1
  • 128
    • 77954229219 scopus 로고    scopus 로고
    • Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects
    • Zhang, W. et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin. Cancer Res. 16, 3420-3430 (2010).
    • (2010) Clin. Cancer Res. , vol.16 , pp. 3420-3430
    • Zhang, W.1
  • 129
    • 48649109203 scopus 로고    scopus 로고
    • Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis
    • Sakurai, T. et al. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 14, 156-165 (2008).
    • (2008) Cancer Cell , vol.14 , pp. 156-165
    • Sakurai, T.1
  • 130
    • 70449732756 scopus 로고    scopus 로고
    • The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis
    • Carmi, Y. et al. The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J. Immunol. 183, 4705-4714 (2009).
    • (2009) J. Immunol. , vol.183 , pp. 4705-4714
    • Carmi, Y.1
  • 131
    • 51349098155 scopus 로고    scopus 로고
    • Cytokines as a key component of cancer-related inflammation
    • Germano, G., Allavena, P. & Mantovani, A. Cytokines as a key component of cancer-related inflammation. Cytokine 43, 374-379 (2008).
    • (2008) Cytokine , vol.43 , pp. 374-379
    • Germano, G.1    Allavena, P.2    Mantovani, A.3
  • 133
    • 25144507526 scopus 로고    scopus 로고
    • Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis
    • DOI 10.1245/ASO.2005.07.015
    • Kubo, F. et al. Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann. Surg. Oncol. 12, 800-807 (2005). (Pubitemid 41355932)
    • (2005) Annals of Surgical Oncology , vol.12 , Issue.10 , pp. 800-807
    • Kubo, F.1    Ueno, S.2    Hiwatashi, K.3    Sakoda, M.4    Kawaida, K.5    Nuruki, K.6    Aikou, T.7
  • 134
    • 17844397949 scopus 로고    scopus 로고
    • The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis
    • DOI 10.1215/S1152851704001061
    • Brat, D. J., Bellail, A. C. & Van Meir, E. G. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro. Oncol. 7, 122-133 (2005). (Pubitemid 40590513)
    • (2005) Neuro-Oncology , vol.7 , Issue.2 , pp. 122-133
    • Brat, D.J.1    Bellail, A.C.2    Van Meir, E.G.3
  • 135
    • 38549175201 scopus 로고    scopus 로고
    • Immunohistochemical expression of stromal cell-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in hepatocellular carcinoma
    • Li, W., Gomez, E. & Zhang, Z. Immunohistochemical expression of stromal cell-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 26, 527-533 (2007). (Pubitemid 351157871)
    • (2007) Journal of Experimental and Clinical Cancer Research , vol.26 , Issue.4 , pp. 527-533
    • Li, W.1    Gomez, E.2    Zhang, Z.3
  • 137
    • 65649140491 scopus 로고    scopus 로고
    • Expression of stem cell factor and its receptor c-Kit during the development of intrahepatic cholangiocarcinoma
    • Mansuroglu, T. et al. Expression of stem cell factor and its receptor c-Kit during the development of intrahepatic cholangiocarcinoma. Lab. Invest. 89, 562-574 (2009).
    • (2009) Lab. Invest. , vol.89 , pp. 562-574
    • Mansuroglu, T.1
  • 138
    • 26044455743 scopus 로고    scopus 로고
    • Correlative study of angiogenesis and dynamic contrast-enhanced magnetic resonance imaging features of hepatocellular carcinoma
    • DOI 10.1080/02841850510021247
    • Wang, B., Gao, Z. Q. & Yan, X. Correlative study of angiogenesis and dynamic contrast-enhanced magnetic resonance imaging features of hepatocellular carcinoma. Acta Radiol. 46, 353-358 (2005). (Pubitemid 41657464)
    • (2005) Acta Radiologica , vol.46 , Issue.4 , pp. 353-358
    • Wang, B.1    Gao, Z.Q.2    Yan, X.3
  • 139
    • 61749091581 scopus 로고    scopus 로고
    • Pancreatic endocrine tumors: Tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors
    • d'Assignies, G. et al. Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology 250, 407-416 (2009).
    • (2009) Radiology , vol.250 , pp. 407-416
    • D'Assignies, G.1
  • 140
    • 34249021801 scopus 로고    scopus 로고
    • Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue - Initial experience
    • DOI 10.1148/radiol.2433052020
    • Sahani, D. V., Holalkere, N. S., Mueller, P. R. & Zhu, A. X. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue - initial experience. Radiology 243, 736-743 (2007). (Pubitemid 46799427)
    • (2007) Radiology , vol.243 , Issue.3 , pp. 736-743
    • Sahani, D.V.1    Holalkere, N.-S.2    Mueller, P.R.3    Zhu, A.X.4
  • 141
    • 40349112983 scopus 로고    scopus 로고
    • Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma
    • DOI 10.1634/theoncologist.2007-0174
    • Zhu, A. X., Holalkere, N. S., Muzikansky, A., Horgan, K. & Sahani, D. V. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist 13, 120-125 (2008). (Pubitemid 351342575)
    • (2008) Oncologist , vol.13 , Issue.2 , pp. 120-125
    • Zhu, A.X.1    Holalkere, N.S.2    Muzikansky, A.3    Horgan, K.4    Sahani, D.V.5
  • 142
    • 79955642250 scopus 로고    scopus 로고
    • Tumor vascularity assessment in hepatocellular carcinoma and disease free caudate and spleen before and after targeted therapy using a distributed parameter model [abstract]
    • Liaw, J V. et al. Tumor vascularity assessment in hepatocellular carcinoma and disease free caudate and spleen before and after targeted therapy using a distributed parameter model [abstract]. Presented at RSNA 2009.
    • (2009) RSNA
    • Liaw, J.V.1
  • 143
    • 69849103783 scopus 로고    scopus 로고
    • Regional chemotherapy for unresectable primary liver cancer: Results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival
    • Jarnagin, W. R. et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann. Oncol. 20, 1589-1595 (2009).
    • (2009) Ann. Oncol. , vol.20 , pp. 1589-1595
    • Jarnagin, W.R.1
  • 144
    • 67650463119 scopus 로고    scopus 로고
    • A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients
    • Sorensen, A. G. et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 69, 5296-5300 (2009).
    • (2009) Cancer Res. , vol.69 , pp. 5296-5300
    • Sorensen, A.G.1
  • 146
    • 74549143750 scopus 로고    scopus 로고
    • Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: Report of two patients with hidradenocarcinoma and trichoblastic carcinoma
    • Battistella, M. et al. Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma. J. Eur. Acad. Dermatol. Venereol. 24, 199-203 (2010).
    • (2010) J. Eur. Acad. Dermatol. Venereol. , vol.24 , pp. 199-203
    • Battistella, M.1
  • 147
    • 77952890743 scopus 로고    scopus 로고
    • Dynamic contrast-enhanced ultrasonography (DCE-US): A new tool for the early evaluation of antiangiogenic treatment
    • Lassau, N. et al. Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatment. Target. Oncol. 5, 53-58 (2010).
    • (2010) Target. Oncol. , vol.5 , pp. 53-58
    • Lassau, N.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.